Belantamab mafodotin

Blenrep 100 MG Polvo Para Concentrado Para Solucion Para Perfusion

100 mg polvo para concentrado para solución para perfusiónSpainWithdrawnAuthorised 23 Sept 2020

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Belantamab mafodotin

Blenrep 100 MG Polvo Para Concentrado Para Solucion Para Perfusion

100 mg polvo para concentrado para solución para perfusiónSpainWithdrawnAuthorised 23 Sept 2020

Product informationAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Blenrep

Italy · Polvere per concentrato per soluzione per infusione · Glaxosmithkline Trading Services Limited

Blenrep 100 mg poeder voor concentraat voor oplossing voor infusieNetherlands · Poeder voor concentraat voor oplossing voor infusie · GlaxoSmithKline Trading Services Limited

Blenrep 70 mg poeder voor concentraat voor oplossing voor infusieNetherlands · Poeder voor concentraat voor oplossing voor infusie · GlaxoSmithKline Trading Services Limited

BlenrepUnited States · 70MG · injectable · Glaxosmithkline LLC

BlenrepUnited States · 100MG · For Injection · GlaxoSmithKline Intellectual Property Development Ltd. England

Packs

Pack	Code	Status
BLENREP 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial	729177

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Belantamab mafodotin
Strength: 100 mg
Dosage form: polvo para concentrado para solución para perfusión
Route: vía intravenosa
Register: Spain (AEMPS)
Status: Withdrawn
Status in the register: Revocado
Authorised: 23 Sept 2020
Registration: 1201474001
Marketing authorisation holder: Glaxosmithkline (Ireland) Limited
Procedure: EU centralised
Supply: Uso Hospitalario
EU number: EU/1/20/1474

Belantamab mafodotin · 77 mg · polvo para concentrado para solución para perfusión

Spain